New combo therapy shows promise for tough esophageal cancer
NCT ID NCT05621707
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment plan for people with advanced esophageal cancer that cannot be surgically removed. Participants first receive immunotherapy plus chemotherapy, followed by chemoradiation. The goal is to see if this approach improves survival and controls the disease. The trial involves 50 adults with good organ function and no prior treatment for this stage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, 200030, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could essential oils tame chemo nausea? a new trial puts aromatherapy to the test
- Shielding the ovaries: a drug may help young breast cancer patients preserve fertility during chemo
- Can surgery for stomach or esophageal cancer cloud the mind?
- Art therapy meets oncology: could mandala coloring boost cancer Patients' well-being?
- Could a chemo boost after radiation tame aggressive prostate cancer?
- Can a targeted drug combo boost chemoradiation in EGFR-Positive lung cancer?